Streetbeat News

Earnings

CSTL

Castle Biosciences (NASDAQ:CSTL) reported Q4 2023 GAAP EPS of $(0.10), surpassing the $(0.61) estimate, with sales of $66.12M exceeding the $56.28M forecast. This represents a 72.47% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

SDGR

Schrodinger's shares have declined following the announcement of mixed financial results for the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

XPER

Xperi reported Q4 2023 adjusted EPS of $0.11, surpassing the $0.05 estimate, but its sales of $137.23M fell short of the $140.18M forecast. This represents a 1.26% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:30 pm

DV

DoubleVerify's stock is trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:29 pm

ACLX

Arcellx reported a strong financial position as of December 31, 2023, with $729.2M in cash and equivalents, expected to fund operations into 2027. Collaboration revenue soared to $110.3M in 2023, thanks to a deal with Kite Pharma. R&D expenses saw a slight increase in Q4 but decreased annually due to accounting treatments. G&A expenses rose due to stock-based compensation, leading to a net income of $20.5M in Q4 2023, a significant improvement from a net loss in the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:29 pm

AI

C3 AI's stock price increased following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:28 pm

ADMA

ADMA Biologics reported Q4 2023 earnings of $0.04 per share, surpassing the consensus estimate of $0.03. Sales reached $73.90M, exceeding the $72.15M estimate and marking a 47.86% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:28 pm

VYGR

Voyager Therapeutics (NASDAQ:VYGR) reported Q4 2023 earnings of $1.25 per share, surpassing the $(0.29) estimate, with sales of $90.06M also beating the $20.64M estimate. This represents a significant increase over the previous year's sales of $(1.55M).

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:27 pm

GOOG

GOOGL

RDDT

Reddit's IPO prospectus reveals a heavy reliance on advertising revenue, a significant partnership with Alphabet Inc. for data licensing, and challenges in turning a profit despite 19 years in operation. The company's valuation expectations above $5 billion raise questions given its current financials and strategy, including a directed share program aimed at creating demand among its user base.

Portfolio Pulse from Surbhi Jain

February 28, 2024 | 9:27 pm

SHLS

Shoals Technologies shares dropped following the announcement of disappointing Q4 financial results and lower than expected revenue guidance for Q1 and FY24.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:27 pm